(Q37570550)

21 August 2017

1 reference

title

Emerging drugs for chronic constipation (English)

1 reference

21 August 2017

Michael D Crowell

1

1 reference

21 August 2017

Lucinda A Harris

series ordinal

2

1 reference

21 August 2017

Tisha N Lunsford

series ordinal

3

1 reference

21 August 2017

John K Dibaise

series ordinal

4

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 September 2009

1 reference

Expert Opinion on Emerging Drugs

21 August 2017

published in

1 reference

21 August 2017

volume

14

1 reference

21 August 2017

issue

3

1 reference

21 August 2017

page(s)

493-504

1 reference

Epidemiology of constipation in North America: a systematic review

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Defecography in multiple sclerosis patients with severe constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Manometric investigation of anorectal function in early and late stage Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Behavioral modification of colonic function. Can constipation be learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Randomized, controlled trial shows biofeedback to be superior to alternative treatments for patients with pelvic floor dyssynergia-type constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Epidemiology of slow and fast colonic transit using a scale of stool form in a community

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Functional bowel disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Systematic review on the management of chronic constipation in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Efficacy and safety of traditional medical therapies for chronic constipation: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

The usual medical care for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

The enteric nervous system: a second brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Review article: tegaserod

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Tegaserod (Zelnorm) for irritable bowel syndrome: reports of serious diarrhea and intestinal ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

A placebo-controlled trial of prucalopride for severe chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Colonoscopy: virtual, optical, or chromoscopic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Mosapride in gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Effect of renzapride on transit in constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Identification of patients with non-d, non-C irritable bowel syndrome and treatment with renzapride: an exploratory, multicenter, randomized, double-blind, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Receptor for motilin identified in the human gastrointestinal system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Contractile effects and intracellular Ca2+ signalling induced by motilin and erythromycin in the circular smooth muscle of human colon

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Mitemcinal (GM-611), an orally active motilin receptor agonist, accelerates colonic motility and bowel movement in conscious dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Mitemcinal (GM-611), an orally active motilin agonist, facilitates defecation in rabbits and dogs without causing loose stools

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Distribution of ClC-2 chloride channel in rat and human epithelial tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

SPI-0211 activates T84 cell chloride transport and recombinant human ClC-2 chloride currents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Basolateral ClC-2 chloride channels in surface colon epithelium: regulation by a direct effect of intracellular chloride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Lubiprostone: a chloride channel activator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Function and dysfunction of mammalian membrane guanylyl cyclase receptors: lessons from genetic mouse models and implications for human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Recognition and signal transduction mechanism of Escherichia coli heat-stable enterotoxin and its receptor, guanylate cyclase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Guanylin stimulation of Cl- secretion in human intestinal T84 cells via cyclic guanosine monophosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Heat-stable enterotoxin of Escherichia coli (STa) can stimulate duodenal HCO3(-) secretion via a novel GC-C- and CFTR-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Uroguanylin and guanylin peptides: pharmacology and experimental therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Pilot study on the effect of linaclotide in patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Opioid-induced bowel dysfunction: pathophysiology and potential new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

The use of quaternary narcotic antagonists in opiate research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Lubiprostone for chronic idiopathic constipation and irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

A review of the potential role of methylnaltrexone in opioid bowel dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Alvimopan, a selective peripherally acting mu-opioid antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Novel opioid antagonists for opioid-induced bowel dysfunction and postoperative ileus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Opioid-induced delay in gastric emptying: a peripheral mechanism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Oral methylnaltrexone for opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Methylnaltrexone for opioid-induced constipation in advanced illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction--a 21-day treatment-randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Clinical trial: alvimopan for the management of post-operative ileus after abdominal surgery: results of an international randomized, double-blind, multicentre, placebo-controlled clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Efficacy and safety of mu-opioid antagonists in the treatment of opioid-induced bowel dysfunction: systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

Cholinergic stimulation and nonadrenergic, noncholinergic relaxation of human colonic circular muscle in idiopathic chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728210903146890

10.1517/14728210903146890

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference